Annual EBIT
-$38.27 M
-$531.00 K-1.41%
31 December 2023
Summary:
Galectin Therapeutics annual earnings before interest & taxes is currently -$38.27 million, with the most recent change of -$531.00 thousand (-1.41%) on 31 December 2023. During the last 3 years, it has fallen by -$14.90 million (-63.72%). GALT annual EBIT is now -1654.00% below its all-time high of -$2.17 million.GALT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$9.73 M
+$1.38 M+12.39%
30 September 2024
Summary:
Galectin Therapeutics quarterly earnings before interest & taxes is currently -$9.73 million, with the most recent change of +$1.38 million (+12.39%) on 30 September 2024. Over the past year, it has dropped by -$133.00 thousand (-1.39%). GALT quarterly EBIT is now -1556.05% below its all-time high of -$587.30 thousand, reached on 30 June 2001.GALT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$40.41 M
-$133.00 K-0.33%
30 September 2024
Summary:
Galectin Therapeutics TTM earnings before interest & taxes is currently -$40.41 million, with the most recent change of -$133.00 thousand (-0.33%) on 30 September 2024. Over the past year, it has dropped by -$965.00 thousand (-2.45%). GALT TTM EBIT is now -6781.49% below its all-time high of -$587.30 thousand, reached on 30 June 2001.GALT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.4% | -1.4% | -2.5% |
| 3 y3 years | -63.7% | -15.7% | -30.7% |
| 5 y5 years | -182.2% | -252.1% | -265.4% |
GALT EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -63.7% | at low | -40.0% | +12.4% | -34.5% | at low |
| 5 y | 5 years | -189.8% | at low | -252.1% | +12.4% | -265.4% | at low |
| alltime | all time | -1654.0% | at low | -1556.0% | +12.4% | -6781.5% | at low |
Galectin Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.73 M(-12.4%) | -$40.41 M(+0.3%) |
| June 2024 | - | -$11.10 M(+6.4%) | -$40.28 M(+7.0%) |
| Mar 2024 | - | -$10.44 M(+14.1%) | -$37.64 M(-1.6%) |
| Dec 2023 | -$38.27 M(+1.4%) | -$9.15 M(-4.6%) | -$38.27 M(-3.0%) |
| Sept 2023 | - | -$9.59 M(+13.3%) | -$39.45 M(+3.3%) |
| June 2023 | - | -$8.46 M(-23.5%) | -$38.19 M(-2.4%) |
| Mar 2023 | - | -$11.07 M(+7.2%) | -$39.10 M(+3.6%) |
| Dec 2022 | -$37.74 M(+25.7%) | -$10.33 M(+24.0%) | -$37.74 M(+9.8%) |
| Sept 2022 | - | -$8.33 M(-11.3%) | -$34.37 M(-0.2%) |
| June 2022 | - | -$9.38 M(-3.3%) | -$34.45 M(+3.1%) |
| Mar 2022 | - | -$9.71 M(+39.7%) | -$33.43 M(+11.3%) |
| Dec 2021 | -$30.04 M(+28.5%) | -$6.95 M(-17.4%) | -$30.04 M(-2.8%) |
| Sept 2021 | - | -$8.41 M(+0.5%) | -$30.92 M(+8.8%) |
| June 2021 | - | -$8.36 M(+32.4%) | -$28.43 M(+8.7%) |
| Mar 2021 | - | -$6.32 M(-19.3%) | -$26.16 M(+11.9%) |
| Dec 2020 | -$23.38 M(+77.0%) | -$7.83 M(+32.2%) | -$23.38 M(+13.1%) |
| Sept 2020 | - | -$5.92 M(-2.8%) | -$20.66 M(+18.0%) |
| June 2020 | - | -$6.09 M(+72.4%) | -$17.50 M(+21.7%) |
| Mar 2020 | - | -$3.53 M(-30.9%) | -$14.39 M(+8.9%) |
| Dec 2019 | -$13.21 M(-2.6%) | -$5.12 M(+85.2%) | -$13.21 M(+19.4%) |
| Sept 2019 | - | -$2.76 M(-7.2%) | -$11.06 M(+0.9%) |
| June 2019 | - | -$2.98 M(+26.5%) | -$10.96 M(-6.6%) |
| Mar 2019 | - | -$2.35 M(-20.8%) | -$11.74 M(-13.4%) |
| Dec 2018 | -$13.56 M(-16.4%) | -$2.97 M(+11.4%) | -$13.56 M(+4.8%) |
| Sept 2018 | - | -$2.67 M(-29.0%) | -$12.94 M(-11.9%) |
| June 2018 | - | -$3.75 M(-10.0%) | -$14.69 M(-4.9%) |
| Mar 2018 | - | -$4.17 M(+77.7%) | -$15.45 M(-4.7%) |
| Dec 2017 | -$16.22 M(-24.3%) | -$2.35 M(-46.8%) | -$16.21 M(-12.0%) |
| Sept 2017 | - | -$4.41 M(-2.2%) | -$18.42 M(-0.7%) |
| June 2017 | - | -$4.51 M(-8.6%) | -$18.54 M(-5.2%) |
| Mar 2017 | - | -$4.94 M(+8.4%) | -$19.56 M(-8.8%) |
| Dec 2016 | -$21.44 M(+6.8%) | -$4.55 M(+0.4%) | -$21.44 M(-0.6%) |
| Sept 2016 | - | -$4.54 M(-18.0%) | -$21.57 M(-5.9%) |
| June 2016 | - | -$5.53 M(-18.8%) | -$22.93 M(+4.0%) |
| Mar 2016 | - | -$6.81 M(+45.5%) | -$22.05 M(+9.8%) |
| Dec 2015 | -$20.08 M(+30.1%) | -$4.68 M(-20.6%) | -$20.08 M(+5.0%) |
| Sept 2015 | - | -$5.90 M(+26.7%) | -$19.13 M(+14.5%) |
| June 2015 | - | -$4.66 M(-3.8%) | -$16.71 M(+8.3%) |
| Mar 2015 | - | -$4.84 M(+29.6%) | -$15.43 M(-0.0%) |
| Dec 2014 | -$15.43 M(+27.5%) | -$3.73 M(+7.4%) | -$15.43 M(+6.4%) |
| Sept 2014 | - | -$3.48 M(+3.0%) | -$14.50 M(-0.5%) |
| June 2014 | - | -$3.38 M(-30.3%) | -$14.57 M(+6.0%) |
| Mar 2014 | - | -$4.84 M(+72.8%) | -$13.74 M(+13.6%) |
| Dec 2013 | -$12.10 M(+22.3%) | -$2.80 M(-20.9%) | -$12.10 M(+1.7%) |
| Sept 2013 | - | -$3.54 M(+39.2%) | -$11.89 M(+7.8%) |
| June 2013 | - | -$2.55 M(-20.5%) | -$11.04 M(-1.0%) |
| Mar 2013 | - | -$3.20 M(+23.2%) | -$11.15 M(+12.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$9.90 M(-9.3%) | -$2.60 M(-3.3%) | -$9.90 M(-11.4%) |
| Sept 2012 | - | -$2.69 M(+1.1%) | -$11.18 M(+6.2%) |
| June 2012 | - | -$2.66 M(+36.4%) | -$10.52 M(-3.1%) |
| Mar 2012 | - | -$1.95 M(-49.7%) | -$10.85 M(-0.6%) |
| Dec 2011 | -$10.91 M(+123.5%) | -$3.88 M(+90.8%) | -$10.91 M(+31.1%) |
| Sept 2011 | - | -$2.03 M(-32.0%) | -$8.33 M(+10.9%) |
| June 2011 | - | -$2.99 M(+48.6%) | -$7.50 M(+28.0%) |
| Mar 2011 | - | -$2.01 M(+56.2%) | -$5.86 M(+20.1%) |
| Dec 2010 | -$4.88 M(-19.9%) | -$1.29 M(+6.4%) | -$4.88 M(+3.7%) |
| Sept 2010 | - | -$1.21 M(-10.2%) | -$4.71 M(-0.8%) |
| June 2010 | - | -$1.35 M(+30.8%) | -$4.75 M(-11.9%) |
| Mar 2010 | - | -$1.03 M(-7.6%) | -$5.39 M(-11.5%) |
| Dec 2009 | -$6.09 M(+14.4%) | -$1.12 M(-10.6%) | -$6.09 M(+0.3%) |
| Sept 2009 | - | -$1.25 M(-37.2%) | -$6.08 M(+5.4%) |
| June 2009 | - | -$1.99 M(+14.9%) | -$5.77 M(+2.1%) |
| Mar 2009 | - | -$1.73 M(+57.5%) | -$5.65 M(+6.0%) |
| Dec 2008 | -$5.33 M(-17.5%) | -$1.10 M(+17.3%) | -$5.33 M(-5.2%) |
| Sept 2008 | - | -$939.00 K(-49.9%) | -$5.62 M(-7.1%) |
| June 2008 | - | -$1.87 M(+32.7%) | -$6.04 M(+1.7%) |
| Mar 2008 | - | -$1.41 M(+1.5%) | -$5.94 M(-7.9%) |
| Dec 2007 | -$6.46 M(-8.4%) | -$1.39 M(+1.7%) | -$6.46 M(+1.5%) |
| Sept 2007 | - | -$1.37 M(-22.8%) | -$6.36 M(-8.1%) |
| June 2007 | - | -$1.77 M(-7.9%) | -$6.92 M(-4.5%) |
| Mar 2007 | - | -$1.92 M(+48.5%) | -$7.25 M(+2.8%) |
| Dec 2006 | -$7.05 M(+5.9%) | -$1.30 M(-32.8%) | -$7.05 M(-6.3%) |
| Sept 2006 | - | -$1.93 M(-8.1%) | -$7.52 M(+3.1%) |
| June 2006 | - | -$2.10 M(+21.8%) | -$7.30 M(+5.4%) |
| Mar 2006 | - | -$1.72 M(-2.5%) | -$6.93 M(+4.1%) |
| Dec 2005 | -$6.66 M(-8.9%) | -$1.77 M(+3.8%) | -$6.66 M(-6.0%) |
| Sept 2005 | - | -$1.71 M(-1.3%) | -$7.08 M(-1.3%) |
| June 2005 | - | -$1.73 M(+18.9%) | -$7.17 M(+4.2%) |
| Mar 2005 | - | -$1.45 M(-33.8%) | -$6.88 M(-5.8%) |
| Dec 2004 | -$7.30 M(+47.9%) | -$2.19 M(+22.0%) | -$7.30 M(+8.8%) |
| Sept 2004 | - | -$1.80 M(+25.2%) | -$6.71 M(+6.3%) |
| June 2004 | - | -$1.44 M(-23.3%) | -$6.31 M(+7.8%) |
| Mar 2004 | - | -$1.87 M(+16.9%) | -$5.86 M(+18.6%) |
| Dec 2003 | -$4.94 M(+50.2%) | -$1.60 M(+14.5%) | -$4.94 M(+11.6%) |
| Sept 2003 | - | -$1.40 M(+42.6%) | -$4.42 M(+20.8%) |
| June 2003 | - | -$981.90 K(+3.0%) | -$3.66 M(+4.0%) |
| Mar 2003 | - | -$953.10 K(-12.5%) | -$3.52 M(+7.2%) |
| Dec 2002 | -$3.29 M(+50.6%) | -$1.09 M(+70.5%) | -$3.29 M(+12.2%) |
| Sept 2002 | - | -$639.00 K(-24.1%) | -$2.93 M(+0.1%) |
| June 2002 | - | -$841.50 K(+17.3%) | -$2.93 M(+9.5%) |
| Mar 2002 | - | -$717.20 K(-2.2%) | -$2.67 M(+36.7%) |
| Dec 2001 | -$2.18 M | -$733.10 K(+15.3%) | -$1.96 M(+59.9%) |
| Sept 2001 | - | -$635.80 K(+8.3%) | -$1.22 M(+108.3%) |
| June 2001 | - | -$587.30 K | -$587.30 K |
FAQ
- What is Galectin Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Galectin Therapeutics?
- What is Galectin Therapeutics annual EBIT year-on-year change?
- What is Galectin Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly EBIT year-on-year change?
- What is Galectin Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Galectin Therapeutics?
- What is Galectin Therapeutics TTM EBIT year-on-year change?
What is Galectin Therapeutics annual earnings before interest & taxes?
The current annual EBIT of GALT is -$38.27 M
What is the all time high annual EBIT for Galectin Therapeutics?
Galectin Therapeutics all-time high annual earnings before interest & taxes is -$2.17 M
What is Galectin Therapeutics annual EBIT year-on-year change?
Over the past year, GALT annual earnings before interest & taxes has changed by -$531.00 K (-1.41%)
What is Galectin Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of GALT is -$9.73 M
What is the all time high quarterly EBIT for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly earnings before interest & taxes is -$587.30 K
What is Galectin Therapeutics quarterly EBIT year-on-year change?
Over the past year, GALT quarterly earnings before interest & taxes has changed by -$133.00 K (-1.39%)
What is Galectin Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of GALT is -$40.41 M
What is the all time high TTM EBIT for Galectin Therapeutics?
Galectin Therapeutics all-time high TTM earnings before interest & taxes is -$587.30 K
What is Galectin Therapeutics TTM EBIT year-on-year change?
Over the past year, GALT TTM earnings before interest & taxes has changed by -$965.00 K (-2.45%)